Amphotericin B in poly(lactic-co-glycolic acid) (PLGA) and dimercaptosuccinic acid (DMSA) nanoparticles against paracoccidioidomycosis

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 3, 2009, Pages 526-533

  Amaral, André C ^a,b   Bocca, Anamélia L ^a   Ribeiro, Alice M ^a   Nunes, Janayna ^a   Peixoto, Danielle L G ^a   Simioni, Andreza R ^c   Primo, Fernando L ^c   Lacava, Zulmira G M ^a   Bentes, Ricardo ^a   Titze de Almeida, Ricardo ^a   Tedesco, Antonio C ^c   Morais, Paulo C ^a   Felipe, Maria Sueli S ^a  

^a UNIVERSITY OF BRASILIA   (Brazil)

^b UNIVERSIDADE CATÓLICA DE BRASÍLIA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antifungal; Drug delivery; Nanobiotechnology; Polymers

Indexed keywords

ALANINE AMINOTRANSFERASE; AMPHOTERICIN B; ASPARTATE AMINOTRANSFERASE; CREATININE; NANOPARTICLE; POLYGLACTIN; SUCCIMER;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BIOCHEMICAL COMPOSITION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SYNTHESIS; ERYTHROCYTE COUNT; FEMALE; GENOTOXICITY; HYPOTRICHOSIS; MICRONUCLEUS TEST; MOUSE; NANOBIOTECHNOLOGY; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; REFLEX; SOUTH AMERICAN BLASTOMYCOSIS; TOXICITY TESTING; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

AMPHOTERICIN B; ANIMALS; BODY WEIGHT; BONE MARROW; COLONY COUNT, MICROBIAL; DEOXYCHOLIC ACID; DRUG COMBINATIONS; FEMALE; KIDNEY; LACTIC ACID; LIVER; LUNG; MICE; MICE, INBRED BALB C; NANOPARTICLES; PARACOCCIDIOIDES; PARACOCCIDIOIDOMYCOSIS; POLYGLYCOLIC ACID; SUCCIMER; TREATMENT OUTCOME;

EID: 60649106758     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn539     Document Type: Article

References (36)

1. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. Clin Infect Dis 2005; 40 Suppl 6: S414-21.
2. Tiphine M, Letscher-Bru V, Herbrecht R. Amphotericin B and its new formulations: Pharmacologic characteristics, clinical efficacy and tolerability. Transpl Infect Dis 1999; 1: 273-83.
3. Khandare J, Minko T. Polymer-drug conjugates: Progress in polymeric prodrugs. Prog Polym Sci 2006; 31: 359-97.
4. Mundargi RC, Babu VR, Rangaswamym V et al. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J Control Release 2008; 125: 193-209.
5. Couvreur P, Vauthier C. Nanotechnology: Intelligent design to treat complex disease. Pharm Res 2006; 23: 1417-50.
6. Dhiman N, Dutta M, Khuller GK. Poly (DL-lactide-co-glycolide) based delivery systems for vaccines and drugs. Indian J Exp Biol 2000; 38: 746-52.
7. Esmaeili F, Hosseini-Nasr M, Rad-Malekshahi M et al. Preparation and antibacterial activity evaluation of rifampicin-loaded poly lactide-co-glycolide nanoparticles. Nanomedicine 2007; 3: 161-7.
8. Jeong YI, Na HS, Seo DH et al. Ciprofloxacin-encapsulated poly(D, L-lactide-co-glycolide) nanoparticles and its antibacterial activity. Int J Pharm 2007; 352: 317-23.
9. Peng HS, Liu XJ, Lv GX et al. Voriconazole into PLGA nanoparticles: Improving agglomeration and antifungal efficacy. Int J Pharm 2008; 352: 29-35.
10. Rivera PA, Martinez-Oharriz MC, Rubio M et al. Fluconazole encapsulation in PLGA microspheres by spray-drying. J Microencapsul 2004; 21: 203-11.
11. Nahar M, Dutta T, Murugesan S et al. Functional polymeric nanoparticles: An efficient and promising tool for active delivery of bioactives. Crit Rev Ther Drug Carrier Syst 2006; 23: 259-318.
12. Chaves SB, Silva LP, Lacava ZGM et al. Interleukin-1 and interleukin-6 production in mice's lung induced by 2,3 mesodimercaptosuccinic-coated magnetic nanoparticles. J Appl Phys 2005; 97: 109-17.
13. Garcia MP, Veloso VN, Lacava ZGM et al. Morphological analysis of mice's lung after treatment with magnetite-based magnetic fluid stabilized with DMSA. J Magn Magn Mater 2005; 293: 277-82.
14. Brummer E, Castaneda E, Restrepo A. Paracoccidioidomycosis: An update. Clin Microbiol Rev 1993; 6: 89-117.
15. de Camargo ZP, de Franco MF. Current knowledge on pathogens and immunodiagnosis of paracoccidioidomycosis. Rev Iberoam Micol 2000; 17: 41-8.
16. Linares LI, Friedman L. Experimental paracoccidioidomycosis in mice. Infect Immun 1972; 5: 681-7.
17. Lortholary O, Denning DW, Dupont B. Endemic mycoses: A treatment update. J Antimicrob Chemother 1999; 43: 321-31.
18. Singer-Vermes LM, Ciavaglia MC, Kashino SS et al. The source of the growth-promoting factor(s) affects the plating efficiency of Paracoccidioides brasiliensis. J Med Vet Mycol 1992; 30: 261-4.
19. Organisation for Economic Co-operation and Development. Guideline for the Testing of Chemicals. Mammalian Erythrocyte Micronucleus Test Adopted. 474. OECD, Paris, 1997.
20. Snyder RD, Green JW. A review of the genotoxicity of marketed pharmaceuticals. Mutat Res 2001; 488: 151-69.
21. Organisation for Economic Co-operation and Development. Guidance Notes for Analysis and Evaluation of Chronic Toxicity and Carcinogenicity Studies. ENV/JM/MONO(2002)19. OECD, Paris, 2002.
22. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49 Suppl S1: 37-41.
23. Olson JA, Adler-Moore JP, Jensen GM et al. Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products. Antimicrob Agents Chemother 2008; 52 259-68.
24. Dupont B. Overview of the lipid formulations of amphotericin. J Antimicrob Chemother 2002; 49 Suppl S1: 31-6.
25. Du L, Cheng J, Chi Q et al. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormone-releasing hormone (LHRH) antagonist. Chem Pharm Bull 2006; 54: 1259-65.
26. Gabler F, Frauenschub S, Ringe J et al. Emulsion-based synthesis of PLGA-microspheres for the in vitro expansion of porcine chondrocytes. Biomol Eng 2007; 24: 515-20.
27. Khang G, Rhee JM, Jeong JK et al. Local drug delivery system using biodegradable polymers. Macromol Res 2003; 11: 207-23.
28. Thomas V, Dean DR, Vohra YK. Nanostructured biomaterials for regenerative medicine. Curr Nanosci 2006; 2: 155-77.
29. Gomes AJ, Barbougli PA, Espreafico EM et al. Trans-[Ru(NO)(NH3)4(py)](BF4)3.H2O encapsulated in PLGA microparticles for delivery of nitric oxide to B16-F10 cells: Cytotoxicity and phototoxicity. J Inorg Biochem 2008; 102: 757-66.
30. Mittal G, Sahana DK, Bhardwaj V. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. J Control Release 2007; 119: 77-85.
31. Chu WS, Jeong SY, Pandey JK et al. Fabrication of composite drug delivery system using nano composite deposition system and in vivo characterization. Int J Precision Eng Manufact 2008; 9: 81-3.
32. Zolnik BS, Burgess DJ. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Control Release 2008; 127: 137-45.
33. Fukui H, Koike T, Saheki A et al. Evaluation of the efficacy and toxicity of amphotericin B incorporated in lipid nano-sphere (LNS). Int J Pharm 2003; 263: 51-60.
34. Reuhl KR, Vapiwala M, Ryzlak MT. Comparative neurotoxicities of amphotericin B and its mono-methyl ester derivative in rats. Antimicrob Agents Chemother 1993; 37: 419-28.
35. Zhang Z, Diener RM, Lipman JM. Safety evaluation of ABELCET, an amphotericin B lipid complex (ABLC): Toxicity studies in rats. Int J Toxicol 2006; 25: 285-94.
36. Charvalos E, Tzatzarakis MN, Van Bambeke F et al. Watersoluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects. J Antimicrob Chemother 2006; 57: 236-44.